Literature DB >> 33374384

Thrombotic Microangiopathy among Hospitalized Patients with Systemic Lupus Erythematosus in the United States.

Aleksandra I Pivovarova1, Charat Thongprayoon2, Panupong Hansrivijit3, Wisit Kaewput4, Fawad Qureshi2, Boonphiphop Boonpheng5, Tarun Bathini6, Michael A Mao7, Saraschandra Vallabhajosyula8, Wisit Cheungpasitporn2.   

Abstract

BACKGROUND: This study aimed to evaluate thrombotic microangiopathy's (TMA) incidence, risk factors, and impact on outcomes and resource use in hospitalized patients with systemic lupus erythematosus (SLE).
METHODS: We used the National Inpatient Sample to construct a cohort of hospitalized patients with SLE from 2003-2014. We compared clinical characteristics, in-hospital treatments, outcomes, and resource use between SLE patients with and without TMA.
RESULTS: Of 35,745 hospital admissions for SLE, TMA concurrently presented or developed in 188 (0.5%) admissions. Multivariable analysis showed that age ≥ 40 years and Hispanics were significantly associated with decreased risk of TMA, whereas Asian/Pacific Islanders and history of chronic kidney disease were significantly associated with increased risk of TMA. TMA patients required more kidney biopsy, plasmapheresis, mechanical ventilation, and renal replacement therapy. TMA was significantly associated with increased risk of in-hospital mortality and acute conditions including hemoptysis, glomerulonephritis, encephalitis/myelitis/encephalopathy, hemolytic anemia, pneumonia, urinary tract infection, sepsis, ischemic stroke, seizure, and acute kidney injury. The length of hospital stays and hospitalization cost was also significantly higher in SLE with TMA patients.
CONCLUSION: TMA infrequently occurred in less than 1% of patients admitted for SLE, but it was significantly associated with higher morbidity, mortality, and resource use.

Entities:  

Keywords:  SLE; hospitalization; mortality; outcomes; risk factor; systemic lupus erythematosus

Year:  2020        PMID: 33374384      PMCID: PMC7838946          DOI: 10.3390/diseases9010003

Source DB:  PubMed          Journal:  Diseases        ISSN: 2079-9721


  21 in total

1.  Evaluation of clinical outcomes and renal vascular pathology among patients with lupus.

Authors:  Claire Barber; Andrew Herzenberg; Ellie Aghdassi; Jiandong Su; Wendy Lou; Gan Qian; Jonathan Yip; Samih H Nasr; David Thomas; James W Scholey; Joan Wither; Murray Urowitz; Dafna Gladman; Heather Reich; Paul R Fortin
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 8.237

2.  Causes and risk factors of death in patients with thrombotic microangiopathies.

Authors:  Vincent Peigne; Pierre Perez; Matthieu Resche Rigon; Eric Mariotte; Emmanuel Canet; Jean-Paul Mira; Paul Coppo; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2012-07-14       Impact factor: 17.440

3.  High rate of death caused by systemic lupus erythematosus among U. S. residents of Asian descent.

Authors:  R A Kaslow
Journal:  Arthritis Rheum       Date:  1982-04

Review 4.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

Review 5.  Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review.

Authors:  K Hamasaki; T Mimura; H Kanda; K Kubo; K Setoguchi; T Satoh; Y Misaki; K Yamamoto
Journal:  Clin Rheumatol       Date:  2003-10       Impact factor: 2.980

6.  Frequency of systemic lupus erythematosus in different ethnic groups in Hawaii.

Authors:  M K Serdula; G G Rhoads
Journal:  Arthritis Rheum       Date:  1979-04

7.  A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus.

Authors:  Pagalavan Letchumanan; Heng-Joo Ng; Lai-Heng Lee; Julian Thumboo
Journal:  Rheumatology (Oxford)       Date:  2009-02-06       Impact factor: 7.580

8.  Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL).

Authors:  G Banfi; T Bertani; V Boeri; T Faraggiana; G Mazzucco; G Monga; G Sacchi
Journal:  Am J Kidney Dis       Date:  1991-08       Impact factor: 8.860

Review 9.  Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

Authors:  Nina Kello; Lara El Khoury; Galina Marder; Richard Furie; Ekaterini Zapantis; Diane Lewis Horowitz
Journal:  Semin Arthritis Rheum       Date:  2018-12-04       Impact factor: 5.532

10.  The spectrum of renal thrombotic microangiopathy in lupus nephritis.

Authors:  Di Song; Li-hua Wu; Feng-mei Wang; Xiao-wei Yang; Di Zhu; Min Chen; Feng Yu; Gang Liu; Ming-hui Zhao
Journal:  Arthritis Res Ther       Date:  2013-01-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.